Baird reiterates Outperform rating on Soleno Therapeutics stock amid short report

Soleno Therapeutics (SLNO) experienced an 18% stock decline following a short report questioning the safety and adoption of its drug Vykat. However, analysts, including Baird, have dismissed these claims as "sensationalized," citing consistent safety profiles and hundreds of commercial treatments. This comes as Soleno reported robust Q2 2025 results, with revenue of $32.7 million significantly exceeding expectations by 113% and better-than-forecasted EPS. Consequently, multiple firms like TD Cowen, Stifel, H.C. Wainwright, and Guggenheim have reiterated or raised price targets, underscoring strong VYKAT sales and a positive company trajectory despite the negative claims and an FDA petition.

Analysis

Soleno Therapeutics (SLNO) is currently at a pivotal juncture, defined by a conflict between a recent short-seller report and exceptionally strong fundamental performance. The stock's 18% decline over the past week was directly triggered by a report alleging safety issues and physician reluctance regarding its drug, Vykat. However, this narrative is strongly contested by the analyst community, with Baird dismissing the claims as "sensationalized" while reiterating an Outperform rating and a $121 price target. The bullish case is substantially reinforced by the company's second-quarter 2025 results, which demonstrated a powerful start for the Vykat launch. Revenue of $32.7 million crushed the $15.35 million consensus estimate by 113%, and the earnings per share of -$0.09 was significantly better than the forecasted -$0.64. This performance has led multiple firms, including TD Cowen, Stifel, and Guggenheim, to raise price targets into the $106-$145 range, indicating a firm belief in the company's trajectory despite the short report and a recently filed FDA Citizen Petition. The situation presents a clear divergence between the current trading price of $68.09 and a strong, data-driven analyst consensus.

Key Decisions for Investors

• Investors should weigh the opportunity presented by the significant gap between the current stock price, depressed by short-seller activity, and the robust analyst price targets which suggest substantial upside.
• Closely monitor upcoming quarterly reports for continued revenue momentum from the VYKAT launch, as sustained outperformance is key to definitively refuting the short thesis.
• Remain vigilant regarding any developments related to the FDA Citizen Petition or new safety data, as these represent the primary tangible risks that could challenge the current bullish analyst consensus.